SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novartis
NVS 123.79+1.0%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark H. Bornfeld who wrote ()3/3/2000 8:19:00 AM
From: Jack Hartmann  Read Replies (1) of 296
 
Novartis, Emisphere Tech Extend Pact To Second Compound
March 2, 2000
Dow Jones Newswires
NEW YORK -- Switzerland's Novartis AG's (Z.NOV) Novartis Pharma AG unit agreed to expand its partnership with Emisphere Technologies Inc. (EMIS) for the oral delivery of a second Novartis compound.

Financial terms weren't disclosed, but Emisphere, a Hawthorne, N.Y., biopharmaceutical company, will receive a cash payment from Novartis under the extension.

Chemical group Novartis said in a press release Thursday that the companies will collaborate to select a second drug compound from several potential drug candidates.

After selecting the compound, Novartis will have nine months to exercise a previously secured option for an exclusive worldwide license to develop and commercialize the compound.

The extended arrangement entitles Emisphere to development and regulatory milestone payments, and potential royalties on product sales and equity investments at the company's option.

In mid-February, Novartis agreed to license drug delivery technology from Emisphere under a joint venture to develop an osteoporosis treatment.

Novartis said recent data suggest Emisphere's oral macromolecule delivery system may serve as a platform for a number of oral protein products.

-Leah McGrath; Dow Jones Newswires; 201-938-5400

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext